These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 38872051)
1. N Yu F; Feng Y; Wang Q; Sun J Cell Biochem Biophys; 2024 Sep; 82(3):2321-2331. PubMed ID: 38872051 [TBL] [Abstract][Full Text] [Related]
2. WTAP-induced N Liu QZ; Zhang N; Chen JY; Zhou MJ; Zhou DH; Chen Z; Huang ZX; Xie YX; Qiao GL; Tu XH Cancer Sci; 2024 Jun; 115(6):1749-1762. PubMed ID: 38508217 [TBL] [Abstract][Full Text] [Related]
3. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961 [TBL] [Abstract][Full Text] [Related]
4. SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion. Chen Z; Yu M; Zhang B; Jin L; Yu Q; Liu S; Zhou B; Yan J; Zhang W; Li X; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Ye Q; Li H; Guo L Oncoimmunology; 2024; 13(1):2376264. PubMed ID: 38988824 [TBL] [Abstract][Full Text] [Related]
5. N Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901 [TBL] [Abstract][Full Text] [Related]
6. RBM12 drives PD-L1-mediated immune evasion in hepatocellular carcinoma by increasing JAK1 mRNA translation. Han H; Shi Q; Zhang Y; Ding M; He X; Liu C; Zhao D; Wang Y; Du Y; Zhu Y; Yuan Y; Wang S; Guo H; Wang Q Oncogene; 2024 Oct; 43(41):3062-3077. PubMed ID: 39187545 [TBL] [Abstract][Full Text] [Related]
7. Exosomal circHIF1A derived from hypoxic-induced carcinoma-associated fibroblasts promotes hepatocellular carcinoma cell malignant phenotypes and immune escape. Shang H; Lu L; Fan M; Lu Y; Shi X; Lu H Int Immunopharmacol; 2024 Sep; 138():112282. PubMed ID: 38936058 [TBL] [Abstract][Full Text] [Related]
8. LRPPRC facilitates tumor progression and immune evasion through upregulation of m Wang H; Tang A; Cui Y; Gong H; Li H Front Immunol; 2023; 14():1144774. PubMed ID: 37063837 [TBL] [Abstract][Full Text] [Related]
9. m Li G; Deng L; Huang N; Cui Z; Wu Q; Ma J; Pan Q; Sun F Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828353 [TBL] [Abstract][Full Text] [Related]
10. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells. Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303 [TBL] [Abstract][Full Text] [Related]
11. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma. Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366 [TBL] [Abstract][Full Text] [Related]
12. EPDR1 promotes PD-L1 expression and tumor immune evasion by inhibiting TRIM21-dependent ubiquitylation of IkappaB kinase-β. Qian X; Cai J; Zhang Y; Shen S; Wang M; Liu S; Meng X; Zhang J; Ye Z; Qiu S; Zhong X; Gao P EMBO J; 2024 Oct; 43(19):4248-4273. PubMed ID: 39152265 [TBL] [Abstract][Full Text] [Related]
13. FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma. Wang Q; Tan W; Zhang Z; Chen Q; Xie Z; Yang L; Tang C; Zhuang H; Wang B; Jiang J; Ma X; Wang W; Hua Y; Shang C; Chen Y Apoptosis; 2024 Oct; 29(9-10):1529-1545. PubMed ID: 38824477 [TBL] [Abstract][Full Text] [Related]
14. Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma. Hu Z; Chen G; Zhao Y; Gao H; Li L; Yin Y; Jiang J; Wang L; Mang Y; Gao Y; Zhang S; Ran J; Li L Mol Cancer; 2023 Mar; 22(1):55. PubMed ID: 36932387 [TBL] [Abstract][Full Text] [Related]
15. SRSF10 facilitates HCC growth and metastasis by suppressing CD8 Luo X; Zhang Z; Li S; Wang Y; Sun M; Hu D; Jiang J; Wang Y; Ji X; Chen X; Zhang B; Liang H; Li Y; Liu B; Xu X; Wang S; Xu S; Nie Y; Wu K; Fan D; Liu D; Huang W; Xia L Int Immunopharmacol; 2024 Jan; 127():111376. PubMed ID: 38113691 [TBL] [Abstract][Full Text] [Related]
16. Hypoxia-responsive lncRNA MIR155HG promotes PD-L1 expression in hepatocellular carcinoma cells by enhancing HIF-1α mRNA stability. Qiu J; Zhong F; Zhang Z; Pan B; Ye D; Zhang X; Yao Y; Luo Y; Wang X; Tang N Int Immunopharmacol; 2024 Jul; 136():112415. PubMed ID: 38850791 [TBL] [Abstract][Full Text] [Related]
17. circATAD2 mitigates CD8 Zhang Z; Huo W; Li J Cancer Immunol Immunother; 2024 May; 73(7):130. PubMed ID: 38748254 [TBL] [Abstract][Full Text] [Related]
18. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma. Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787 [TBL] [Abstract][Full Text] [Related]
19. High expression of circulating exosomal PD-L1 contributes to immune escape of hepatocellular carcinoma and immune clearance of chronic hepatitis B. Lin X; Shao H; Tang Y; Wang Q; Yang Z; Wu H; Xing T Aging (Albany NY); 2024 Jul; 16(14):11373-11384. PubMed ID: 39028365 [TBL] [Abstract][Full Text] [Related]
20. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity. Tao Z; Ruan H; Sun L; Kuang D; Song Y; Wang Q; Wang T; Hao Y; Chen K Cancer Immunol Res; 2019 Jul; 7(7):1135-1147. PubMed ID: 31113805 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]